Compare McCormick & Company, Incorporated (MKC) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
McCormick & Company, Incorporated vs TransMedics Group Inc — how do they compare? McCormick & Company, Incorporated trades at $52.97 (market cap $14.24B), while TransMedics Group Inc trades at $86.7 (market cap $3.02B). The key difference: McCormick & Company, Incorporated is far larger — about 4.7× TransMedics Group Inc's market cap, and McCormick & Company, Incorporated pays a 3.62% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MKC | TMDX | |
|---|---|---|
Market Cap | $14.24B | $3.02B |
Sector | Consumer Staples | Technology |
52-Week High | $72.26 | $150.42 |
52-Week Low | $45.60 | $61.99 |
Enterprise Value | $18.84B | $3.41B |
Dividend Yield | 3.62% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
McCormick (MKC) trades at $52.93, down 0.38% on the day, with a bullish technical signal from moving averages but neutral oscillators. The stock shows strong fundamentals with a P/E of 8.8, net income margin of 21.91%, and consistent earnings beats. Recent news highlights the transformative $65 billion merger with Unilever's food business, expected to complete in 2027, driving positive analyst sentiment and a consensus price target of $59.67.
The outlook for MKC is positive, supported by margin expansion, strategic acquisitions, and the potential upside from the Unilever deal. Key risks include integration challenges from the merger, soft consumer volumes, and competitive pressures. With a 4% dividend yield and 35% upside to some price targets, the stock presents a compelling opportunity for long-term investors despite near-term volatility.
TransMedics Group (TMDX) trades at $87.02, down 1.57% today, amid mixed signals. The stock shows a bullish technical trend with moving averages supporting upside, but oscillators like RSI indicate overbought conditions near 78. Fundamentally, the company reported record Q2 2026 revenue but missed earnings estimates, with net income margin declining to 22.69% from 31.42% in 2025. Recent news highlights an ongoing investigation into fiduciary duties by Rosen Law Firm, adding uncertainty.
The outlook remains cautiously optimistic with a consensus price target of $99.57, implying 14% upside, supported by strong analyst buy ratings (69%). However, risks include earnings volatility, margin pressure from rising costs, and legal scrutiny. Investors should weigh robust revenue growth against execution risks and elevated valuation multiples like a P/E of 23.15.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About McCormick & Company, Incorporated
In its 130-year history, McCormick has grown to become the leading global manufacturer, marketer, and distributor of spices, herbs, extracts, seasonings, and other flavorings. Beyond end consumers, McCormick's customer base also includes top quick-service restaurants, retail grocery chains, and other packaged food and beverage manufacturers, with about 30% of sales generated beyond its home turf to include 150 other countries and territories. In addition to its namesake brand, the firm's portfolio includes Old Bay, Zatarain's, Thai Kitchen, Frank's RedHot, French's, and the recently acquired Cholula brand.
Read more on MKC →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
